ArticleBMC complementary medicine and therapies2026
Integrated network pharmacology and bioinformatics analysis reveals MME as key target of Notoginsenoside R1 in diabetic nephropathy.
Article in BMC complementary medicine and therapies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundDiabetic nephropathy (DN) is a major diabetes complication and a primary cause of end-stage renal failure. Notoginsenoside R1 (NGR1) is known to reduce proteinuria, exert hypoglycemic effects, and enhance renal function in DN patients. However, the exact mechanisms by which NGR1 affects DN are not well understood.
methodsAn integrative approach combining multi-omics bioinformatics and experimental validation was employed. We analyzed GEO datasets (GSE30122, GSE96804) to identify differentially expressed genes and performed WGCNA to define key modules. Network pharmacology predicted NGR1 targets, which were refined via machine learning (LASSO and Random Forest). Immune infiltration was assessed by CIBERSORT. Molecular docking and dynamics simulations evaluated binding interactions. In vitro functional validation used high glucose (HG)-injured MPC5 podocytes, with MME-specific inhibitor (Thiorphan), confirming target necessity.
resultsBioinformatic analysis identified three core targets, MME, PTGS2, and S100A9, within the DN pathological network. Functional enrichment revealed their involvement in oxidative stress detoxification, TGF-β-mediated fibrosis, and AGE-RAGE signaling pathways. Immune infiltration analysis indicated an aberrant increase in M0/M2 macrophages and activated mast cells, alongside a reduction in protective γδ T cells, with core targets showing strong correlations with specific immune subsets. Subsequent molecular docking and dynamics simulations indicated that NGR1 exhibited the strongest binding affinity for MME, among the three targets. Corroborating these findings, in vitro experiments confirmed that NGR1 specifically upregulates MME expression transcriptionally and translationally. Crucially, NGR1 counteracted HG-induced oxidative stress, fibrosis, and inflammation. These protective effects were largely abolished upon MME inhibition, demonstrating MME's essential role in this process.
conclusionThis study suggests that NGR1 may exert renoprotective effects in DN potentially through MME modulation, which appears to mitigate oxidative stress, inflammation, and fibrosis. The findings indicate MME could serve as a promising therapeutic target, providing preliminary mechanistic insights for developing targeted DN therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.